Calls › JNJ › Oct 14, 2026

JNJ Neutral Johnson & Johnson · Healthcare

Reaction overdone, but no cheap edge.

Published Oct 14, 2026 · Horizon 3-6 months Audited

Edgenone claimed

Evidence7/10

Entry (close)

$248.61 2026-10-13

Since publish

+8.1% to 2026-10-27

vs SPY

+9.2%

3-month verdict

Closes 2027-01-12

Thesis

JNJ delivered a genuine operational beat (6% operational sales growth, Tremfya +68%, raised guidance) but the market correctly identified quality issues: Darzalex decelerating (+16% but below consensus), Stelara erosion (-54%), a MedTech sales miss, and Innovative Medicine margin collapsing from 44.3% to 35.4% on acquired IPR&D and mix. The guidance 'raise' only partially recovers the $0.64 July cut caused by the Firefly/Sail acquisitions, so FY26 EPS expectations are still well below mid-July levels. The sell-off was statistically extreme relative to the news — largely a positioning/valuation reset after a 33% one-year run at the top of JNJ's forward P/E range.

Bull case

The sell-off is an overreaction to one-time optics: adjusted EPS beat, guidance was raised, Tremfya is growing 68% and absorbing Stelara losses, the talc resolution (if the 95% threshold is met) removes the largest legal overhang in the sector, and sell-side targets ($282-290) imply 13-16% upside from $248. A 0.24-beta stock that just had a 1.75-sigma idiosyncratic flush on a beat-and-raise historically mean-reverts; the 10.7% drawdown from the 52-week high at RSI ~30 supports that.

Bear case

The market is right to reprice: adjusted operational EPS growth guidance is only ~2%, Darzalex — the largest growth engine — decelerated and missed, MedTech missed in what should be the stable segment, and management is buying growth via dilutive acquisitions ($0.64 EPS hit) rather than generating it organically. At ~22x forward earnings with Stelara's biosimilar cliff still in progress and the talc deal not final, there is no valuation cushion if FY27's $12.26 consensus starts to slip.

What would change our mind

If FY27 consensus EPS of $12.26 is cut materially (e.g., below ~$11.80) after Q4 earnings, the 'trough year' thesis fails and the multiple likely compresses further
If the talc participation threshold is not met or the deal collapses, the de-risking leg of the bull case is void
If Darzalex misses consensus again in Q4, treat the Q3 miss as trend, not noise
If the stock holds above ~$260 on no new fundamental news within 3 months, the flush was purely technical and the dip-buy thesis worked

**JNJ's one-year run set up the sharp reset.** JNJ's strong outperformance versus the market and healthcare over the past year helps explain why a mixed beat triggered an outsized post-earnings sell-off.

Since publication vs SPY · closed horizons are frozen

1 weekfinal

+5.8%

+4.3% raw

1 monthrunning

+9.2%

+8.1% raw

3 monthsrunning

+9.2%

+8.1% raw

6 monthsrunning

+9.2%

+8.1% raw

The full research everything the view rests on

Direct answer to the question asked

Read the quarter as a mixed one, not a miss: the beat-and-raise was real but low-quality — Darzalex and MedTech missed, Innovative Medicine margins compressed sharply, and the 'raised' FY26 EPS guidance ($11.10 midpoint) is still ~$0.58 below the pre-acquisition July level. The ~6% drop on a beat was violent for a 0.24-beta stock (1.75-sigma, 89th-percentile vol) and looks like an expectations reset after a +32% one-year run at ~22x forward, not fundamental deterioration. At $248 the reaction is arguably overdone versus sell-side targets (~$282-290), but JNJ is not cheap enough to make that a high-conviction trade.

Where the edge would come from

What the price assumes

Heading into the print, JNJ was up 32.6% over one year (vs SPY +19.1%), trading at ~21-22x forward earnings near the top of its recent range, with 6 of 7 analysts at Buy and an average target just under $290. A clean beat-and-raise with no blemishes was substantially priced in; the market was paying for acceleration, and instead got 2% adjusted operational EPS growth guidance.

Why the market may be wrong

The drop was almost entirely idiosyncratic (60-day SPY correlation -0.08) and disproportionate: analysts actually raised targets post-print (RBC to $290 Outperform, BofA to $282 Hold), the talc charge is one-time and the proposed resolution removes a decades-long overhang, and the Firefly/Sail margin hit is acquired IPR&D — an accounting charge for pipeline investment, not operating decay. If Darzalex's miss proves one-off and MedTech's weakness is geopolitical/transitory, the market punished a 2% EPS-growth year at 22x while ignoring that the talc resolution could unlock a re-rating.

The one thing to watch

The variable to watch is not the talc headline or the $0.09 reported EPS — it is whether FY2027 consensus of $12.26 (+10.7%) survives the next two quarters, because that estimate implicitly assumes Darzalex re-accelerates and MedTech normalizes; the stock's ~22x multiple only works if 2026's ~2% adjusted operational EPS growth is a trough, not a trend.

Key evidence (8)

Q3 2026 sales $25.4B, +5.9% reported / +6.0% operational; adjusted EPS $2.59 vs ~$2.52-2.53 consensus [T1 JNJ earnings presentation, 10/13/26]
Reported EPS $0.09 (net income -96% to $210M) on talc resolution and Firefly/Sail charges; press characterizes talc charge ~$5.5B, but figures of ~$8B and >$9B nominal also cited — only partially verified [T1 SEC/IR; T3/T4 press]
FY26 guidance raised to adjusted EPS $11.05-11.15 (midpoint $11.10, +$0.06) but still ~$0.58 below the July 15 midpoint of $11.68 after the July 29 acquisition-driven $0.64 cut [T1 SEC 8-K 7/29/26]
Darzalex +16% to $4.24B vs ~$4.4B expected (miss); Stelara -54% to $716M; Tremfya +68% to $2.4B (beat) [T3 CNBC coverage]
Innovative Medicine margin fell 44.3% to 35.4%, driven by ~$1B acquired IPR&D and mix; MedTech sales missed on Middle East/geopolitics though margin improved to 22.9% [T3]
Stock fell ~6% on the print; 1-month return -1.75 sigma vs own history, 20d vol at 89th percentile, volume 2.2x average, 60-day correlation to SPY -0.08 (idiosyncratic) [quant analysis]
Talc resolution is an agreement in principle (~$5.5B nominal, ~76,000 claims) requiring >=95% claimant participation; not court-approved or final as of Oct 2026 [T2/T4, partially verified]
Post-earnings: RBC raised target to $290 (Outperform), BofA to $282 (Hold); pre-earnings average target just under $290 [T3/T4]

Catalysts and risks

Catalysts

Q4 2026 earnings on 2027-01-26 (consensus EPS ~$3.02, revenue ~$26.8B) — first look at FY27 guidance
Talc settlement participation milestone: confirmation that >=95% of claimants opted in, and court approval steps
Darzalex quarterly trajectory — whether the Q3 miss was competitive or transitory
RYBREVANT FASPRO priority review decision in head-and-neck cancer; OTTAVA robotics rollout
JNJ 10-Q filing clarifying the true size/structure of the talc charge ($5.5B vs $8-9B nominal)

Risks

Talc deal fails the 95% participation threshold, reopening trial risk and potentially a larger ultimate liability
Darzalex miss signals competitive erosion, putting the +10.7% FY27 EPS consensus at risk
Continued acquisition-driven EPS dilution and margin compression from IPR&D charges
MedTech weakness persists beyond geopolitical one-offs
Valuation: ~22x forward is the top of JNJ's recent range for ~2% EPS growth

What to watch

FY2027 EPS estimate revisions — the single most important number
Talc claimant opt-in rate and any court rulings on the settlement
Darzalex and Tremfya prescription/sales trends into Q4
MedTech order commentary and ex-US growth (only +1.8% in Q3)
Whether the 10-Q confirms the talc charge at ~$5.5B or closer to $8-9B nominal

Market snapshot when the call was made 2026-10-13

Price

Return 1w	-2.4%
Return 1m	-6.7%
Return 3m	+0.6%
Return 6m	+4.1%
Return 1y	+32.6%
From 52-week high	-10.7%
Realized vol, 20d	26.6%
SPY 3m / 1y	+3.1% / +19.1%
QQQ 3m / 1y	+3.6% / +26.1%

Technicals

JNJ technicals as of 2026-10-13: last close $248.61; 20d SMA 263.63 (neutral); 50d SMA 265.37; 12d EMA 259.41; 26d EMA 262.48; RSI 14 30.1 (balanced); 20d vol 26.1%; volume x2.2 vs 20d avg

Next earnings: 2027-01-26 AMC

Sources (22 · T1 = primary filings)

Want a fresh look at JNJ, or another name?

Queue a new deep-research run. Published to the feed when done.

Automated research opinion, published as-is on Oct 14, 2026. Not personalised advice. Figures use end-of-day closes.